David Esposito has been named to the Board of Directors at Shield Diagnostics, an Andreessen Horowitz-backed biotechnology company tackling antibiotic resistance by bringing precision medicine to infectious disease. "I am pleased to welcome David to our board of directors. His guidance, expertise and deep commitment to patient care will help strengthen Shield as we advance our mission of preventing antibiotic resistance with diagnostics," said Fred Turner, Shield Diagnostics CEO and Chairman.
Mr. Esposito is currently the CEO of ONL Therapeutics based in Ann Arbor. He is the former CEO of Armune BioScience where he led the development and commercialization of blood-based diagnostics to enable more personalized treatment for cancer. Armune BioScience was sold to Exact Sciences in 2017. Previously, Esposito was President of Phadia US Inc. (allergy and autoimmune diagnostics) and played a pivotal role in selling the business to Thermo Fisher Scientific in 2011. Mr. Esposito was recognized with a Bronze Star for combat action in Iraq in 1991.
"I am honored to join the Shield Board of Directors," said Mr. Esposito. "Shield's technology of rapid molecular testing for antibiotic susceptibility provides an answer to the crisis of antibiotic resistance. It is one that will change the infectious disease space, and I am excited to help this innovative and talented team in this great mission." Read more.